William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $146.03, for a total transaction of $1,562,374.97. Following the transaction, the chief executive officer owned 301,185 shares in the company, valued at $43,982,045.55. This trade represents a 3.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

William Lewis also recently made the following trade(s):

• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $150.97, for a total value of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total transaction of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total transaction of $1,786,412.03.

Insmed Stock Performance

Insmed stock traded down $6.31 during mid-day trading on Thursday, hitting $143.57. The company had a trading volume of 2,269,771 shares, compared to its average volume of 2,554,283. The company’s fifty day moving average is $159.98 and its 200-day moving average is $165.37. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The company has a market capitalization of $30.95 billion, a price-to-earnings ratio of -22.40 and a beta of 1.13. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same period in the prior year, the business posted ($1.32) EPS. Insmed’s revenue was up 152.6% compared to the same quarter last year. Equities research analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Hedge Funds Weigh In On Insmed

Hedge funds have recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Insmed in the 4th quarter worth $506,625,000. Vanguard Group Inc. raised its holdings in Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after purchasing an additional 2,291,328 shares in the last quarter. RTW Investments LP lifted its position in Insmed by 57.0% in the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after purchasing an additional 1,758,321 shares during the period. Artisan Partners Limited Partnership boosted its holdings in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares in the last quarter. Finally, Orbis Allan Gray Ltd purchased a new stake in Insmed in the 2nd quarter valued at approximately $153,389,000.

Analyst Ratings Changes

INSM has been the topic of a number of recent analyst reports. The Goldman Sachs Group upped their target price on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Leerink Partners reiterated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. UBS Group lowered their price target on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday, January 6th. Citigroup reissued an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Finally, Morgan Stanley set a $166.00 price objective on shares of Insmed in a research report on Friday, February 20th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $207.52.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.